Thanks for including a model! I hope that future Forum posts with cost-effectiveness models do the same (some other posts have, but not all).
I’m confused about the “ten years” figure you chose. I didn’t see it mentioned in the Longevity Panel’s report, or in de Grey’s (though I may have missed something). Why start with that number for the DALY estimation, rather than one year?
It didn’t come from either, it came from me, as a benchmark for what seems conservatively possible to achieve in the near-term, and for the size of impact necessary to be plausibly cost-competitive with other causes like global poverty. (If the same amount of funding yielded only one year’s delay in the DALY burden of age-related diseases, I think that would make global poverty likely to be a “better buy.”)
Thanks for including a model! I hope that future Forum posts with cost-effectiveness models do the same (some other posts have, but not all).
I’m confused about the “ten years” figure you chose. I didn’t see it mentioned in the Longevity Panel’s report, or in de Grey’s (though I may have missed something). Why start with that number for the DALY estimation, rather than one year?
It didn’t come from either, it came from me, as a benchmark for what seems conservatively possible to achieve in the near-term, and for the size of impact necessary to be plausibly cost-competitive with other causes like global poverty. (If the same amount of funding yielded only one year’s delay in the DALY burden of age-related diseases, I think that would make global poverty likely to be a “better buy.”)